Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antibody Structure and Classes01:25

Antibody Structure and Classes

859
Antibodies, also known as immunoglobulins, are produced by B cells in response to foreign substances, such as bacteria and viruses. These proteins are critical for recognizing and neutralizing these substances, protecting the body from potential harm.
The basic structure of an antibody consists of four protein chains: two identical heavy chains and two identical light chains. These chains are held together by disulfide bonds and other non-covalent interactions, forming a Y-shaped structure.
859
Antibody Actions01:26

Antibody Actions

1.1K
Antibodies, or immunoglobulins, are critical players in the immune system's arsenal against invading pathogens. Produced by B cells and plasma cells, their primary role is to detect and bind to specific antigens, molecules found on the surface of pathogens like bacteria or viruses. Beyond antigen recognition, antibodies perform several vital functions that contribute to immune defense.
Neutralization
Antibodies can bind to pathogens, preventing them from infecting host cells. This process...
1.1K
Antibody Structure01:10

Antibody Structure

59.6K
Overview
Antibodies, also known as immunoglobulins (Ig), are essential players of the adaptive immune system. These antigen-binding proteins are produced by B cells and make up 20 percent of the total blood plasma by weight. In mammals, antibodies fall into five different classes, which each elicits a different biological response upon antigen binding.
The Y-Shaped Structure of Antibodies Consists of Four Polypeptide Chains
Antibodies consist of four polypeptide chains: two identical heavy...
59.6K
Hybridoma Technology01:31

Hybridoma Technology

14.2K
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
14.2K
Phase II Conjugation Reactions: Overview01:14

Phase II Conjugation Reactions: Overview

173
Conjugation, a key component of phase II biotransformation reactions, is a vital process in drug detoxification. It involves transferring endogenous substances like glucuronic acid, sulfate, and glycine to drugs or their metabolites formed in phase I reactions. These conjugation reactions, often catalyzed by specific enzymes, transform potentially harmful metabolites into inactive, water-soluble forms easily excreted in urine or bile. By enhancing polarity and eliminating pharmacological...
173
Affinity and Avidity01:41

Affinity and Avidity

35.9K
Overview
35.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Glycan Remodeling Technologies for Enhancing Antibody Function.

Advances in experimental medicine and biology·2026
Same author

C-mannosyl tryptophan dynamics in a mouse model of the peritoneal dissemination of ovarian cancer.

The Journal of biological chemistry·2026
Same author

Site-Specific Glycan Conjugation Improves Stability and Efficacy of an Antibody-Drug Conjugates Bearing DXd as a Cytotoxic Payload.

ACS omega·2026
Same author

Attenuated Toxicity and Antitoxic Mechanism via Sodium Iodide Symporter Inhibition-Based Tumor-Selective Delivery in Astatine-211 Radioimmunotherapy.

Molecular pharmaceutics·2026
Same author

Meflin is a druggable target using antibody-drug conjugates in progressive osteosarcoma.

Oncogene·2025
Same author

C-Mannosyl tryptophan is a novel biomarker for thrombocytosis of myeloproliferative neoplasms.

Scientific reports·2024

Related Experiment Video

Updated: Jun 15, 2025

Genetic Encoding of a Non-Canonical Amino Acid for the Generation of Antibody-Drug Conjugates Through a Fast Bioorthogonal Reaction
11:02

Genetic Encoding of a Non-Canonical Amino Acid for the Generation of Antibody-Drug Conjugates Through a Fast Bioorthogonal Reaction

Published on: September 14, 2018

7.7K

[Basics and Innovations in Antibody-Drug Conjugates].

Shino Manabe1

  • 1Hoshi University, Laboratory of Synthetic Biomolecular Chemistry.

Gan to Kagaku Ryoho. Cancer & Chemotherapy
|August 27, 2024
PubMed
Summary
This summary is machine-generated.

Antibody-drug conjugates (ADCs) leverage targeted delivery for enhanced cancer therapy. Advanced strategies and cancer immunology insights are crucial for maximizing their sustained therapeutic impact.

More Related Videos

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting
11:58

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting

Published on: March 8, 2018

7.6K
Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics DCAF
09:39

Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics DCAF

Published on: September 17, 2019

6.8K

Related Experiment Videos

Last Updated: Jun 15, 2025

Genetic Encoding of a Non-Canonical Amino Acid for the Generation of Antibody-Drug Conjugates Through a Fast Bioorthogonal Reaction
11:02

Genetic Encoding of a Non-Canonical Amino Acid for the Generation of Antibody-Drug Conjugates Through a Fast Bioorthogonal Reaction

Published on: September 14, 2018

7.7K
Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting
11:58

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting

Published on: March 8, 2018

7.6K
Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics DCAF
09:39

Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics DCAF

Published on: September 17, 2019

6.8K

Area of Science:

  • Oncology
  • Immunology
  • Pharmacology

Background:

  • Antibody-drug conjugates (ADCs) are established cancer therapeutics.
  • Ongoing research aims to further advance ADC technology.
  • Understanding ADC structure, mechanism, and tumor microenvironment interactions is key.

Purpose of the Study:

  • To provide an overview of ADC structure and mechanism of action.
  • To explore methods for generating homogeneous ADCs and bystander effects.
  • To discuss next-generation ADC strategies and their integration with immunotherapy.

Main Methods:

  • Review of ADC components (antibody, payload, linker) and their functions.
  • Analysis of ADC mechanisms including antigen binding, internalization, and drug release.
  • Exploration of innovative ADC approaches like radioimmunotherapy and photoimmunotherapy.

Main Results:

  • ADCs expand the therapeutic window by targeted delivery and controlled release.
  • Homogeneous ADC generation and bystander effects enhance efficacy.
  • Next-generation strategies and immunotherapy integration show promise.

Conclusions:

  • ADC efficacy relies on targeted delivery, controlled release, and cancer immunology.
  • Understanding underlying mechanisms is vital for sustained therapeutic impact.
  • Further research into ADC integration with other therapies is warranted.